Ceremed Launches New Biopor® Line at the 2015 ASPS Meeting in Boston

Los Angeles, October 22, 2015

Ceremed, Inc. launched Biopor® Porous Polyethylene Implants, a new product line for use in maxillofacial reconstruction and augmentation, at the 2015 meeting of the American Society of Plastic Surgeons (ASPS), the largest plastic surgery specialty organization in the world and a leading authority on cosmetic and reconstructive plastic surgery. Biopor® implants are made of high-density porous polyethylene (HDPE) whose network of open, interconnected pores supports fibrovascular ingrowth and integration of the implanted device with surrounding tissue. Optional water-soluble AOC® coating uniquely available with the new Biopor® line reduces “tissue grab” and minimizes debris accumulation within the pores, making implants easier to insert into tissue pockets. “We are very pleased to see the high interest generated by our new product and especially the innovative polymer coating we introduced to the surgeons at the ASPS,” said Ceremed’s President Tadeusz Wellisz, MD, himself a reconstructive surgeon.

The AOC® coating is part of Ceremed's portfolio of proprietary AOC® PolymerBlend™ technology based on Alkylene Oxide Copolymers commonly used in the medical field. This unique polymer blend is an ideal implant coating material – it becomes slippery when wet, dissolves without swelling, and is eliminated from the body within 48 hours. Unlike most resorbable polymers, AOC® PolymerBlend™ does not require metabolic or inflammatory processes to break down.

Founded in 2002, Ceremed is a privately held medical device company focused on meeting the needs of today’s surgeons by designing and developing innovative medical materials using proprietary AOC® PolymerBlend™ technology.

Ceremed Launches Biopor® Porous Polyethylene Product Line

Los Angeles, October 14, 2015

Ceremed, Inc. announced today the launch of Biopor® Porous Polyethylene Implants, a new product line for use in maxillofacial reconstruction and augmentation. Biopor® implants are made of high-density porous polyethylene (HDPE) whose network of open, interconnected pores supports fibrovascular ingrowth and integration of the implanted device with surrounding tissue. Optional water-soluble AOC® coating uniquely available with the new Biopor® line reduces “tissue grab” and minimizes debris accumulation within the pores, making implants easier to insert into tissue pockets.

The AOC® coating is part of Ceremed's portfolio of proprietary AOC® PolymerBlend™ technology based on Alkylene Oxide Copolymers commonly used in the medical field. This unique polymer blend is an ideal implant coating material – it becomes slippery when wet, dissolves without swelling, and is eliminated from the body within 48 hours. Unlike most resorbable polymers, AOC® PolymerBlend™ does not require metabolic or inflammatory processes to break down.

Founded in 2002, Ceremed is a privately held medical device company focused on meeting the needs of today’s surgeons by designing and developing innovative medical materials using proprietary AOC® PolymerBlend™ technology.

Ostene® Brand Acquired by Baxter International, Inc.

August 17, 2011

Ceremed, Inc. (Los Angeles) announced today that it has entered into a definitive agreement to sell its Ostene® brand bone hemostasis product line to Baxter International Inc. The agreement provides for Baxter to acquire all rights to the Ostene® brand, including manufacturing.

Founded in 2002, Ceremed is a privately held medical device company focusing on the design and development of medical materials, utilizing their proprietary AOC PolymerBlend™ technology. Ceremed has successfully commercialized applications ranging from coatings and carriers to bone hemostasis. Based on the proven safety, efficacy and versatility of the AOC PolymerBlend™ technology, Ceremed looks forward to the continued development and innovation of products that meet the needs of today’s surgeons.

“We are very pleased that Baxter has agreed to acquire the Ostene® brand.” said Tadeusz Wellisz, M.D., chairman of Ceremed.

With the divestiture of both the marketing and manufacturing of Ostene®, Ceremed will free up assets needed to focus on bringing new products to market that will meet the demands of patients and device manufacturers alike. “This is a great opportunity for Ceremed to take the next step to becoming a major player in the biomaterials market,” noted Bill Lamm, president of Ceremed.

Details of the financial terms of the agreement are not being disclosed. For further information regarding Ceremed or its products, please contact info@ceremed.com

Ceremed's AOC PolymerBlend™ Awarded Best New Technology in Biomaterials for Spine Care in 2010

Octobor 5, 2010

ORLANDO, Fla., Oct 05, 2010 -- Ceremed's patented implantable polymer material known as AOC PolymerBlend™ won Orthopedics This Week's annual award for Best New Technology for Spine Care in 2010 in the Biomaterials category. AOC PolymerBlend™ was selected winner by a panel of neurosurgeons, orthopedic surgeons and veteran clinical buyers, based on the technology's originality, clinical relevance, and the likelihood that it will improve current standards of care.

"I am proud of AOC PolymerBlend™'s success," said Ceremed's chairman, Tadeusz Wellisz, M.D." AOC PolymerBlend™ is a versatile technology that has been well received by physicians and scientists. This award serves as continued validation for AOC PolymerBlend™ as Ceremed strives to develop more products that aid the surgeon and improve the patient's quality of care."

AOC PolymerBlend™ is Ceremed's proprietary implantable polymer material. It is composed of a blend of Alkylene Oxide Copolymers that are commonly used in the medical field. This unique blend is an ideal carrier because it dissolves without swelling and is eliminated from the body within 48 hours. Unlike most resorbable polymers, AOC PolymerBlend™ does not require metabolic or inflammatory processes to break down. AOC PolymerBlend™ is synthetic and can be formulated in a range of consistencies with a unique combination of properties, including anhydrous formulations, making it an ideal carrier for compounds that are not stable in aqueous solutions. The material is proving to be a versatile, soluble carrier that delivers a broad range of therapeutics to the surgical site without compromising the healing process.

AOC PolymerBlend™ is already used in spinal fusion products, as a soluble coating system for orthopedic and neurosurgical implants, and for bone hemostasis. Ceremed is able to custom-manufacture compounds using any OEM proprietary material in combination with biomaterial.

About Ceremed:
Founded in 2002, Ceremed is a privately held medical device company focusing on the design and development of medical materials, utilizing their proprietary AOC PolymerBlend™ technology. Ceremed has successfully commercialized applications ranging from coatings and carriers to bone hemostasis. Based on the proven safety, efficacy and versatility of the AOC PolymerBlend™ technology, Ceremed looks forward to the continued development and innovation of products that meet the needs of today’s surgeons.

SOURCE Ceremed, Inc.

Ceremed Awarded Third NIH Grant to Develop Soluble Hemostatic Carriers for Targeted Delivery of Therapeutic Agents to The Surgical Site

September 2, 2010

Los Angeles, CA (September 2, 2010) -- Ceremed, Inc. was awarded a Small Business Innovation Research (SBIR) grant, the company’s third in a series of grants from the National Institutes of Health to develop a versatile soluble carrier with bone hemostatic properties for targeted delivery of therapeutic agents directly to surgical sites. The recently awarded grant will aid Ceremed in its effort to develop a soluble carrier to topically deliver the antibiotic Vancomycin.

Topical delivery of therapeutics is a valuable tool in securing better patient outcomes, particularly in many common cardiac, orthopedic, spinal, and neurosurgical procedures. Ceremed’s anhydrous, soluble, and highly malleable carrier is made of proprietary AOC PolymerBlend™ material. Applied to cut bone, the AOC PolymerBlend™ carrier will control bleeding and release therapeutic agents as it dissolves without compromising the healing process.

The AOC PolymerBlend™ formulation with Vancomycin, in combination with a carrier for the antibiotic Gentamicin, under development thanks to an earlier NIH grant, will target both susceptible and methycillin-resistant (MRSA) organisms to help prevent post operative infections, reduce the cost of potentially preventable complications, and improve patient outcomes across surgical fields. The third grant in the series was awarded for the development of an AOC PolymerBlend™ carrier for DBM. AOC PolymerBlend™ with DBM allows for stable delivery of bone growth factors directly to the bone, strengthens bone fusion, and promotes significantly earlier onset of healing and postoperative recovery without increased risk of complications.

“Utilizing the AOC PolymerBlend™ material for delivery of therapeutics has great potential to continue improving patient outcomes across surgical fields,” said Ceremed’s Chairman Tadeusz Wellisz, MD. “Ceremed has experienced success in developing soluble carriers for DBM and Gentamicin, and we look forward to continued success in the development of AOC PolymerBlend™ Vancomycin.”

About AOC PolymerBlend™:
AOC PolymerBlend™ is Ceremed’s proprietary implantable polymer material. It is composed of a blend of Alkylene Oxide Copolymers that are commonly used in the medical field. This unique blend is an ideal carrier because it dissolves without swelling and is eliminated from the body within 48 hours. To dissolve, the material does not require metabolic or inflammatory processes as most resorbable polymers do. AOC PolymerBlend™ is synthetic and can be formulated in a range of consistencies with a unique combination of properties, including anhydrous formulations, making it an ideal carrier for compounds that are not stable in aqueous solutions. The material is proving to be a versatile, soluble carrier that delivers a broad range of therapeutics to the surgical site, without compromising the healing process.

AOC PolymerBlend™ is already used in spinal fusion products, as a soluble coating system for orthopedic and neurosurgical implants, and for bone hemostasis. Ceremed is able to custom-manufacture compounds using any OEM proprietary material in combination with the AOC PolymerBlend™ biomaterial.

About Ceremed:
With the divestiture of both the marketing and manufacturing of Ostene®, Ceremed will free up assets needed to focus on bringing new products to market that will meet the demands of patients and device manufacturers alike. “This is a great opportunity for Ceremed to take the next step to becoming a major player in the biomaterials market,” noted Bill Lamm, president of Ceremed.

Research leading to the formulation of AOC PolymerBlend™ carriers was supported by NIH Awards # 1R43HL092732, 1R43 HL104840, and 1R41AR056177 from the National Institute Of Arthritis And Musculoskeletal And Skin Diseases and from the National Heart, Lung and Blood Institute. The studies were solely the responsibility of Ceremed, Inc. and do not necessarily represent the official views of the National Institutes of Health.

Ceremed Announces Collaborative Effort to Produce ApaTech's New Spinal Implant Actifuse™ Shape

Oct. 14, 2008

LOS ANGELES, Oct. 14, 2008 -- Ceremed Inc. announced today that its collaborative effort with ApaTech Limited, a London based manufacturer of products for bone grafting, has resulted in the launch of ApaTech's latest product, Actifuse™ Shape, a novel, formable bone grafting solution. The new product combines Ceremed's AOC PolymerBlend™ technology with ApaTech's proprietary Actifuse™ microgranules. The resulting product's biostimulative properties are optimized by AOC's ability to be molded or cut to the contours of the grafting site.

The synthetic blend of alkylene oxide copolymers in AOC PolymerBlend™ is water soluble allowing them to dissolve. The unique properties of the product include the dissolution of the product without swelling or inflammation as seen with some implant materials. The dissolved product is then eliminated from the body without further breakdown.

The launch of Actifuse Shape represents the culmination of a two year collaborative effort between the companies. The product will be manufactured in Ceremed's Los Angeles facility and shipped to ApaTech's distribution points in the UK and US. Ceremed has licensed the AOC PolymerBlend™ technology to ApaTech Limited as the first of many projects in which the AOC PolymerBlend™ technology is used as a passive carrier for bioactive materials and therapeutic agents. Several other derivative products related to the AOC PolymerBlend™ technology are planned for release in the coming year.

"Ceremed is committed to the design and development of unique medical polymers to enhance the effectiveness of surgical procedures," says Tadeusz Wellisz, M.D., CEO of Ceremed. "We are actively seeking strategic alliances that greatly expand the impact of our products on the medical market. Ceremed's ability to rapidly bring products to market combined with the expertise in developing unique polymer blends makes us an exceptional partner for co-development."

Ceremed, Inc. is a privately held California medical device corporation that has a unique expertise in the field of medical polymers. The company maintains manufacturing facility in Los Angeles and is a FDA registered medical device manufacturer. A major focus of the company is the development of strategic alliances with medical device companies to co-develop or license the company's polymer materials.

Ceremed Inc.